Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Limertinib ± bevacizumab in EGFR-mutant NSCLC after third-generation EGFR-TKI failure
ChiCTR2600119645Phase 2Not yet recruiting
- Sponsor
- Anhui Chest Hospital
- Start
- Mar 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in non-small cell lung cancer (NSCLC) comparing Single drug group (limertinib) with Combination group (limertinib + bevacizumab) (2 arms). Primary endpoint: progression-free survival. Planned start Mar 2026; status: not yet recruiting.
02
Drugs
limertinibbevacizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2600119645.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600119645.